Dengue Vaccine Globally
- A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people ages 9-45 years old. The World Health Organization recommends that the vaccine only be given to persons with confirmed prior dengue virus infection.
- The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not been previously infected with a dengue virus may be at risk of developing severe dengue if they get dengue after being vaccinated.
Dengue Vaccine in the United States
- In May 2019, Dengvaxia® was approvedexternal icon by the U.S. Food and Drug Administration (FDA) in the United States for use in children 9-16 years old living in an area where dengue is common (the US territories of American Samoa, Puerto Rico and the US Virgin Islands), with laboratory confirmed prior dengue virus infection.
- Information on the vaccine’s availability in the US territories is pending.
If you are interested in getting vaccinated with Dengvaxia
- Talk to your healthcare provider.
- Three doses of vaccine are required. Each shot is spaced 6 months apart.
Page last reviewed: September 23, 2019